We may also have missed individuals with advanced DME diagnosed too late to be treated, or macular edema not significantly impacting visual acuity (DME IVTs are reimbursed in France for patients with visual acuity ≤70 ETDRS letters) and not treated by anti-VEGF or dexamethasone injections. This evidence concerns the gene VEGFA and macular retinal edema.